70
Participants
Start Date
December 15, 2021
Primary Completion Date
February 29, 2024
Study Completion Date
August 15, 2024
Levosimendan
administration of levosimendan as a continuous iv. infusion, every 4 weeks for 48 weeks (12 infusions in total)
Placebo
administration of glucose as a continuous iv. infusion, every 4 weeks for 48 weeks (12 infusions in total)
Medical University of Bialystok Clinical Hospital, Bialystok
Medical University Hospital No.1, Bydgoszcz
Medical University Hospital No.2, Bydgoszcz
Uniwersyteckie Centrum Kliniczne, Gdansk
Górnośląskie Centrum Medyczne Śląskiego Uniwersytetu Medycznego, Katowice
Szpital Uniwersytecki w Krakowie, Krakow
John Paul II Hospital, Krakow
Provincial Specialist Hospital named after Dr. Wł. Biegański, Lodz
Medical University Hospital, Opole
University Hospital of Lord's Transfiguration, Poznan
Uniwersyteckie Centrum Kliniczne Warszawskiego Uniwersytetu Medycznego, Warsaw
Cardinal Stefan Wyszyński Institute of Cardiology, Warsaw
Uniwersytecki Szpital Kliniczny, Wroclaw
Śląskie Centrum Chorób Serca, Zabrze
Collaborators (1)
Medical Research Agency, Poland
OTHER_GOV
University of Opole
OTHER
Medical University of Lodz
OTHER
Poznan University of Medical Sciences
OTHER
Nicolaus Copernicus University
OTHER
National Institute of Cardiology, Warsaw, Poland
OTHER
Azienda Ospedaliera dei Colli
OTHER
John Paul II Hospital, Krakow
OTHER
Medical University of Bialystok
OTHER